262 related articles for article (PubMed ID: 12629058)
1. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
Itoh K; Ohtsu T; Sasaki Y; Ogura M; Morishima Y; Kasai M; Chou T; Yoshida K; Ohno T; Mizorogi F; Uike N; Sai T; Taniwaki M; Ikeda S; Tobinai K
Leuk Lymphoma; 2000 Aug; 38(5-6):521-32. PubMed ID: 10953973
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
4. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
7. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
8. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
9. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of single-dose G-CSF in mobilization and reconstruction of allogeneic peripheral blood stem cell transplantation].
Tian H; Zhou SY
Ai Zheng; 2003 Dec; 22(12):1325-9. PubMed ID: 14693061
[TBL] [Abstract][Full Text] [Related]
11. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.
Ahn JS; Park S; Im SA; Yoon SS; Lee JS; Kim BK; Bang SM; Cho EK; Lee JH; Jung CW; Kim HC; Seong CM; Lee MH; Kim CS; Lee KS; Lee JA; Ahn MJ
Korean J Intern Med; 2005 Sep; 20(3):224-31. PubMed ID: 16295781
[TBL] [Abstract][Full Text] [Related]
12. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
13. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
15. The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.
D'Hondt L; Emmons RV; André M; Guillaume T; Feyens AM; Canon JL; Humblet Y; Longueville J; Symann M
Leuk Lymphoma; 1999 Jun; 34(1-2):105-9. PubMed ID: 10350337
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
17. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
[TBL] [Abstract][Full Text] [Related]
19. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]